ClinVar Miner

Submissions for variant NM_000321.3(RB1):c.1519G>C (p.Asp507His)

dbSNP: rs2138144909
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV002027081 SCV002311178 uncertain significance Retinoblastoma 2023-10-22 criteria provided, single submitter clinical testing This sequence change replaces aspartic acid, which is acidic and polar, with histidine, which is basic and polar, at codon 507 of the RB1 protein (p.Asp507His). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with RB1-related conditions. ClinVar contains an entry for this variant (Variation ID: 1517078). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on RB1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Sema4, Sema4 RCV002256892 SCV002530796 uncertain significance Hereditary cancer-predisposing syndrome 2021-12-08 criteria provided, single submitter curation
Ambry Genetics RCV002256892 SCV002708150 uncertain significance Hereditary cancer-predisposing syndrome 2022-04-22 criteria provided, single submitter clinical testing The p.D507H variant (also known as c.1519G>C), located in coding exon 17 of the RB1 gene, results from a G to C substitution at nucleotide position 1519. The aspartic acid at codon 507 is replaced by histidine, an amino acid with similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Laboratory of Molecular Epidemiology of Birth Defects, West China Second University Hospital, Sichuan University RCV003154233 SCV003843667 likely pathogenic Ovarian cancer 2022-01-01 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.